deltatrials
Terminated PHASE1 INTERVENTIONAL 5-arm NCT04625205

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Sponsor: BioNTech US Inc.

Conditions Metastatic Melanoma Unresectable Melanoma
Interventions IL-2 NEO-PTC-01 PD-1 Inhibitors
Updated 24 times since 2020 Last updated: Apr 3, 2025 Started: Dec 1, 2020 Primary completion: Mar 26, 2025 Completion: Mar 26, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other Metastatic Melanoma trials with similar outcome

Browse all Metastatic Melanoma trials

This PHASE1 trial investigates Metastatic Melanoma and Unresectable Melanoma and is currently terminated or withdrawn. BioNTech US Inc. leads this study, which shows 24 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~May 2025 · 4 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. May 2025 — Sep 2025 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  3. Jan 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Nov 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 19 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE1

  5. Nov 2023 — Mar 2024 [monthly]

    Recruiting PHASE1

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  7. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  8. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  10. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1

  11. Jan 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  12. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

  13. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  14. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  15. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  16. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  17. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  18. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  19. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioNTech US Inc.
Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations